# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN
- Date: 2026-03-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Matthias Lindqvist, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for three months of cough, two weeks of blood-streaked sputum, night sweats, and weight loss: chest X-ray and CT, sputum samples, blood tests, home airborne isolation, and a report of suspected tuberculosis to the health department. **S**

## Objective

Hemoglobin: 12.1 g/dL (low); White cell count: 9.6 10*3/uL; Platelets: 442 10*3/uL (high); ALT: 18 U/L; AST: 24 U/L; Total bilirubin: 0.5 mg/dL; Alkaline phosphatase: 84 U/L; Albumin: 3.2 g/dL (low); Creatinine: 0.78 mg/dL; eGFR: 125 mL/min/1.73 m²; Glucose: 86 mg/dL; Potassium: 4 mmol/L; Calcium: 9 mg/dL; Magnesium: 2 mg/dL; PHQ-9: 7; AUDIT-C: 2. All results are synthetic.

BP 104/66 mmHg; pulse 102 bpm; respirations 20/min; temperature 37.9 °C; oxygen saturation 95% on room air; weight 48.5 kg; BMI 16.8 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture; Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Infectious diseases consultation to confirm the diagnosis, choose between the six-month and four-month regimens, plan monitoring and his return to teaching, and address cystic fibrosis and alpha-1 antitrypsin deficiency as explanations for his lifelong chest illness. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022) **S**
- Diagnosis: three sputum samples at least eight hours apart, one early in the morning, for acid-fast smear, nucleic acid amplification with rifampin resistance, culture, molecular testing for isoniazid and fluoroquinolone resistance, and phenotypic susceptibility; an interferon-gamma release assay; HIV, hepatitis B, and hepatitis C tests; and baseline blood count, liver and kidney tests, potassium, calcium, and magnesium. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022) **S**
- Infection control and public health: home airborne isolation with no students or visitors and a surgical mask around others; same-day report of suspected tuberculosis to the health department; a contact investigation of his students, friends, and other close contacts led by the health department. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005) **S**
- Nutrition: two dietitian visits in the first month, three meals and three energy-dense snacks a day, two oral nutrition supplement drinks a day, and weight at every visit. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012) **S**
- Support: plain information about how tuberculosis spreads, how quickly treatment makes him non-infectious, and that it is curable; help with what to tell his students; PHQ-9 at diagnosis, at two months, and at the end of treatment. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Depression and Suicide Risk in Adults: Screening (2023) **S**
